CL

Collplant Biotechnologies LtdNASDAQ CLGN Stock Report

Last reporting period 30 Sep, 2024

Updated 20 Dec, 2024

Last price

Market cap $B

0.055

Micro

Exchange

XNAS - Nasdaq

CLGN Stock Analysis

CL

Uncovered

Collplant Biotechnologies Ltd is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-6/100

Low score

Market cap $B

0.055

Dividend yield

Shares outstanding

11.011 B

CollPlant Biotechnologies Ltd. operates as a regenerative and aesthetic medicine company. The firm provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).

View Section: Eyestock Rating